Acute Liver Failure—Hospital Workup and Management

Introduction

Acute liver failure (ALF) is a rare, rapidly progressive, and potentially reversible syndrome characterized by abrupt loss of hepatic function, resulting in coagulopathy and hepatic encephalopathy within 26 weeks of symptom onset in patients without preexisting liver disease. ALF carries a high mortality rate, approaching 50% without transplantation, and requires urgent diagnosis, etiological determination, and aggressive multiorgan support. Early referral to a liver transplant center is essential to optimize outcomes. [1][2]

Learning Objectives

1. Define acute liver failure and distinguish it from acute-on-chronic liver failure using clinical and diagnostic criteria.
2. Conduct a systematic diagnostic evaluation to determine etiology, including appropriate laboratory testing, imaging, and targeted workup.
3. Apply prognostic scoring systems (King’s College Criteria, MELD) to guide transplant referral decisions.
4. Implement evidence-based intensive care management strategies including neuroprotection, infection control, and multiorgan support.

Definition and Classification

ALF is defined by:

• Illness duration 26 weeks or less.

• Coagulopathy (INR ≥1.5).

• Any degree of hepatic encephalopathy.

• Absence of preexisting cirrhosis (exceptions: autoimmune hepatitis, Budd-Chiari syndrome, Wilson disease). [1][2][3][4]

• O’Grady Classification:

  • Hyperacute: Encephalopathy within 7 days (e.g., acetaminophen, HAV, HEV, ischemia); highest risk of cerebral edema, best prognosis.
  • Acute: Encephalopathy 8–28 days (e.g., HBV).
  • Subacute: Encephalopathy 29 days to 26 weeks (e.g., non-acetaminophen DILI); lower risk of cerebral edema, worse prognosis without transplant. [1][5]

• It is critical to distinguish ALF from acute-on-chronic liver failure (ACLF), which occurs in patients with underlying cirrhosis and often presents with stigmata of chronic liver disease. [1]

Etiology and Differential Diagnosis

Etiology varies geographically and influences prognosis and management. [1][2]

Common causes include:

• Drug-induced: Acetaminophen (accounts for ~50% of US cases), idiosyncratic DILI (antibiotics, NSAIDs, herbal supplements, immune checkpoint inhibitors). [2][3]
• Viral: HAV, HBV (± HDV), HEV (notably in pregnancy), HSV, VZV, EBV, CMV, dengue, adenovirus, COVID-19. [2][2]
• Autoimmune: Autoimmune hepatitis, which may present acutely despite underlying fibrosis. [1][6]
• Vascular: Budd-Chiari syndrome, ischemic hepatitis (“shock liver”), acute heart failure. [3]
• Metabolic: Wilson disease (fulminant presentation with high bilirubin, low alkaline phosphatase, bilirubin/ALP ratio >2.0), acute fatty liver of pregnancy (AFLP), HELLP syndrome. [6]
• Toxins: Amanita phalloides (mushroom poisoning), yellow phosphorus. [2]
• Indeterminate: Up to 11% of cases remain undiagnosed despite extensive workup. [2][6]

Initial Assessment

History>

• Timeline of symptom onset.
• Medication review (prescription, OTC, herbal, supplements, etc).
• Alcohol use and risk factors.
• Viral exposure history. Travel history.
• Suicidal ideation. Overdose risk?
• Family history (especially for Wilson disease).
• Pregnancy status.
• Recent hypotension or shock events.
• Signs and symptoms of cirrhosis?

Physical Exam>

• Vital signs. Stable or unstable? Do they need the ICU? Shock? Sepsis?
• Jaundice?
• Mental status assessment (West-Haven Criteria for encephalopathy grading). Can they protect their airway?
• Signs of chronic liver disease (should be absent).
• Asterixis.
• Pupillary reflexes. S/s concerning for cerebral edema?
• West-Haven Criteria for Hepatic Encephalopathy:
  • Grade 1: Mild confusion, altered sleep, attention deficit.
  • Grade 2: Lethargy, disorientation—prompt ICU transfer.
  • Grade 3: Somnolence, severe confusion, responsive to stimuli—consider intubation.
  • Grade 4: Coma, unresponsive—intubate for airway protection.

Diagnostic Workup

Laboratory Evaluation

• Initial labs: CBC, CMP, LFTs (AST, ALT, bilirubin, alkaline phosphatase, albumin), PT/INR, arterial ammonia, acetaminophen level, alcohol level, ethyl glucuronide or phosphatidylethanol if alcohol suspected, lactate, arterial blood gas, blood type and screen. [1]
• Etiology-specific testing:
  • Viral serologies: Anti-HAV IgM, HBsAg, anti-HBc IgM, HBV DNA, anti-HCV, HCV RNA, anti-HEV IgM, HSV PCR, VZV PCR, EBV PCR, CMV PCR. [6]
  • Autoimmune: ANA, anti-smooth muscle antibody, anti-LKM, IgG levels. [6]
  • Metabolic: Ceruloplasmin (low in 50% of ALF, not specific), 24-hour urine copper, slit lamp for Kayser-Fleischer rings, pregnancy test. [6]
  • Toxicology: Acetaminophen adducts (if available), comprehensive drug screen, review controlled substance databases. [6]

Imaging

• Abdominal ultrasound with Doppler (assess liver size, texture, rule out cirrhosis, evaluate hepatic vasculature for Budd-Chiari).
• CT abdomen if ultrasound is inadequate.
• Head CT if high-grade encephalopathy to rule out alternative diagnoses or hemorrhage. [1][2]

Liver Biopsy

• Consider transjugular biopsy in indeterminate cases; coagulopathy is not a contraindication with this approach. [6]

Pattern Recognition

• Acetaminophen: Very high transaminases (>10,000), relatively low bilirubin initially, hyperacute presentation, history may be obscured by encephalopathy or denial. [6]
• Ischemic hepatitis: Extreme transaminase elevation (>5,000), rapid normalization, recent hypotension/cardiac arrest, low bilirubin initially. [6]
• Wilson disease: Young patient, Coombs-negative hemolytic anemia, low alkaline phosphatase with high bilirubin (ratio >2.0), acute renal failure. [6]
• Autoimmune hepatitis: Young to middle-aged women, elevated IgG, positive autoantibodies, subacute presentation. [6]
• Viral: Moderate transaminase elevation, appropriate epidemiologic exposure. [2]
• Budd-Chiari: Abdominal pain, ascites, hepatomegaly, caudate lobe hypertrophy on imaging. [3]

Prognostic Assessment and Transplant Referral

Prognostic Scoring Systems

• King’s College Criteria (KCC):

  • Acetaminophen ALF: pH 7.3 after resuscitation OR all three: INR >6.5, creatinine >3.4 mg/dL, grade 3–4 encephalopathy.
  • Non-acetaminophen ALF: INR >6.5 OR any three of five: age 10 or >40 years, etiology (non-A/non-B hepatitis, halothane, idiosyncratic drug), jaundice to encephalopathy >7 days, INR >3.5, bilirubin >17.5 mg/dL. [1][2]

• MELD Score: MELD >25 is associated with high mortality and is more accurate for non-acetaminophen ALF. [1][2]

• Clinical Predictors: High-grade encephalopathy (grades 3–4), vasopressor requirement, mechanical ventilation, acute kidney injury, subacute etiology. [2][4]

• Key Decision Points:

  • Transfer to ICU: Grade 2 encephalopathy or higher.
  • Intubation: Grade 3–4 encephalopathy for airway protection.
  • Initiate CRRT: Ammonia >150–200 μmol/L, AKI, or volume overload.
  • Contact transplant center: At diagnosis of ALF, ideally before encephalopathy develops.
  • List for transplant: KCC met, MELD >25, or clinical deterioration despite maximal therapy. [1][2][4]

• Transplant Considerations:

  • Early communication with transplant center is crucial.
  • Status 1a criteria: ICU care plus one of—mechanical ventilation, continuous RRT, or INR >2 with encephalopathy onset 56 days from jaundice. [2][4]
  • Contraindications: Uncontrolled sepsis, irreversible brain injury, advanced cardiopulmonary disease, active substance use, metastatic malignancy. [4]
  • Outcomes: 1-year survival post-transplant 79–84%; spontaneous survival now exceeds 50% with optimal intensive care. [2][6]

Intensive Care Management

Monitoring

• Continuous cardiorespiratory monitoring.
• Frequent neurologic assessments, pupillary checks every 2–4 hours.
• Hourly glucose checks.
• Serial arterial ammonia levels.
• Daily labs: CBC, CMP, coagulation, lactate. [7]

Neuroprotection

• Head elevation to 30° to reduce intracranial pressure.
• Sedation with short-acting agents (propofol, fentanyl) if intubated; avoid long-acting benzodiazepines.
• Seizure management: Short-acting benzodiazepines for active seizures; prophylactic antiepileptics not recommended.
• Osmotherapy: Maintain serum sodium 140–145 mEq/L with hypertonic saline (if needed) to prevent cerebral edema.
• Avoid hypotension, hypoxia, hypoglycemia, hyperglycemia, fever, hypocapnia, agitation. [8][7]

Hyperammonemia Management

• Continuous renal replacement therapy (CRRT) is first-line, even without AKI; initiate when ammonia >150–200 μmol/L.
• Lactulose and rifaximin are NOT effective in ALF and may worsen encephalopathy; reserved for ACLF. [9][7]

Renal Support

• Early CRRT for AKI, hyperammonemia, or volume overload.
• Use regional citrate anticoagulation when possible given coagulopathy. [9][7]

Hemodynamic Support

• Vasopressors (norepinephrine first-line) for MAP ≥65 mmHg.
• Aggressive fluid resuscitation may worsen cerebral edema; consider pulmonary artery catheter for complex shock. [7]

Respiratory Support

• Low threshold for intubation with grade 3–4 encephalopathy.
• Target normocapnia (PaCO2 35–40 mmHg); hypocapnia worsens cerebral edema. [8][7]

Infection Prevention

• High index of suspicion—25–30% develop bacterial/fungal infections.
• Surveillance cultures every 48 hours.
• Empiric broad-spectrum antibiotics for sepsis.
• Prophylactic antibiotics NOT routinely recommended. [7]

Coagulopathy Management

• Do NOT routinely correct INR (needed for prognostication).
• Give FFP/platelets only for active bleeding or before invasive procedures.
• Consider recombinant factor VIIa for refractory bleeding. [7]

Metabolic Management

• Frequent glucose monitoring (target 140–180 mg/dL); dextrose infusions often required.
• Correct electrolytes aggressively. [7]

Etiology-Specific Therapies

• Acetaminophen: N-acetylcysteine—continue until INR improves, mental status clears, or transplant/death; improves transplant-free survival in early acetaminophen ALF; may benefit non-acetaminophen ALF. [8]
• Autoimmune hepatitis: Corticosteroids are controversial—may improve outcomes if diagnosed early but worsen infection risk and outcomes in advanced disease. [8]
• Hepatitis B: Tenofovir or entecavir—initiate immediately if HBsAg positive. [1]
• Herpes viruses: Acyclovir 10 mg/kg IV every 8 hours for HSV/VZV. [1]
• Wilson disease: Zinc, penicillamine NOT effective acutely; urgent liver transplant evaluation. [6]
• Budd-Chiari: Anticoagulation, TIPS, consider thrombolysis. [1]
• Amanita poisoning: Penicillin G, N-acetylcysteine, silibinin (if available). [1]

Emerging Therapies

• Plasma Exchange: High-volume plasma exchange (HVPE) may improve transplant-free survival in grade 2–3 encephalopathy; improves hemodynamics and reduces vasopressor requirement; standard-volume plasma exchange used as bridge to transplant. [9][8]
• Albumin Dialysis: Molecular adsorbent recirculating system (MARS)—insufficient evidence for routine use; may serve as bridge to transplant. [6]
• Hypothermia: Therapeutic hypothermia (32–34°C) for refractory intracranial hypertension—limited evidence but may be considered. [8]

Common Pitfalls

• Misdiagnosis: Missing acute-on-chronic liver failure—look for stigmata of cirrhosis, imaging findings, thrombocytopenia. [1]
• Delayed Referral: Waiting too long to contact transplant center—should occur early, ideally before encephalopathy develops. [1]
• Coagulopathy Correction: Routinely correcting INR obscures prognosis and wastes blood products without proven benefit. [7]
• Lactulose Use: Ineffective in ALF and may worsen encephalopathy; reserved for ACLF. [9]
• Unrecognized Acetaminophen: Acetaminophen adducts can identify occult toxicity; pattern of very high transaminases with low bilirubin. [6]
• Cerebral Edema Signs: Subtle changes in mental status, pupillary changes, hypertension with bradycardia (Cushing reflex)—requires immediate intervention. [8]
• Infection Underdiagnosis: Fever and leukocytosis may be absent; maintain high suspicion and low threshold for cultures and empiric antibiotics. [7]

Summary
Acute liver failure is a medical emergency requiring rapid diagnosis, etiological determination, and aggressive multiorgan support. Early referral to a liver transplant center is essential, guided by validated prognostic models such as King’s College Criteria and MELD score. Intensive care management focuses on neuroprotection, infection control, and support of failing organs. Etiology-specific therapies and emerging interventions may further improve outcomes, but timely transplantation remains the definitive treatment for selected patients. Vigilance for pitfalls and early intervention are critical to optimizing survival. [1][2][2][7]

References

1. Shingina A, Mukhtar N, Wakim-Fleming J, et al. Acute Liver Failure Guidelines. The American Journal of Gastroenterology. 2023;118(7):1128-1153. doi:10.14309/ajg.0000000000002340.
2. Maiwall R, Kulkarni AV, Arab JP, Piano S. Acute Liver Failure. Lancet (London, England). 2024;404(10454):789-802. doi:10.1016/S0140-6736(24)00693-7.
3. Saner FH, Scarlatescu E, Gold A, et al. Advanced Strategies for Intensive Care Management of Acute Liver Failure. Best Practice & Research. Clinical Gastroenterology. 2024;73:101962. doi:10.1016/j.bpg.2024.101962.
4. Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (Baltimore, Md.). 2014;59(3):1144-65. doi:10.1002/hep.26972.
5. Tujios S, Stravitz RT, Lee WM. Management of Acute Liver Failure: Update 2022. Seminars in Liver Disease. 2022;42(3):362-378. doi:10.1055/s-0042-1755274.
6. Lee WM, Stravitz RT, Larson AM. Introduction to the Revised American Association for the Study of Liver Diseases Position Paper on Acute Liver Failure 2011. Hepatology (Baltimore, Md.). 2012;55(3):965-7. doi:10.1002/hep.25551.
7. Nilsen O, Fisher C, Warrillow S. Update on the Management of Acute Liver Failure. Current Opinion in Critical Care. 2025;31(2):219-227. doi:10.1097/MCC.0000000000001253.
8. Vento S, Cainelli F. Acute Liver Failure in Low-Income and Middle-Income Countries. The Lancet. Gastroenterology & Hepatology. 2023;8(11):1035-1045. doi:10.1016/S2468-1253(23)00142-5.
9. Nanchal R, Subramanian R, Alhazzani W, et al. Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations. Critical Care Medicine. 2023;51(5):657-676. doi:10.1097/CCM.0000000000005824.